A study on the association of serum 1,5-anhydroglucitol levels and the hyperglycaemic excursions as measured by continuous glucose monitoring system among people with type 2 diabetes in China

Diabetes/Metabolism Research and Reviews

Volumn 28, Issue 4, 2012, Pages 357-362

  Wang, Y ^a   Zhang, Y L ^a,b   Wang, Y P ^a,b   Lei, C H ^a,b   Sun, Z L ^a  

^a AFFILIATED ZHONGDA HOSPITAL OF SOUTHEAST UNIVERSITY   (China)

^b SOUTHEAST UNIVERSITY   (China)

Author keywords

1,5 anhydroglucitol; Hyperglycaemic excursions; Type 2 diabetes mellitus

Indexed keywords

1,5 ANHYDROSORBITOL; GLUCOSE; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CHINA; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC PATIENT; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

ADULT; AGED; AREA UNDER CURVE; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; CHINA; DEOXYGLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84860897474     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2278     Document Type: Article

References (23)

1. Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. N Engl J Med 2010; 362: 1090-1101.
2. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996; 39: 1577-1583.
3. Muggeo M, Zoppini G, Bonora E, et al. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care 2000; 23: 45-50.
4. Jones SC, Saunders HJ, Qi W, Pollock CA. Intermittent high glucose enhances cell growth and collagen synthesis in cultured human tubulointerstitial cells. Diabetologia 1999; 42: 1113-1119.
5. Schmitz O, Juhl CB, Lund S, et al. HbA1c does not reflect prandial plasma glucose excursions in type 2 diabetes. Diabetes Care 2000; 23: 1859-1860.
6. Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K, Hanefeld M. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 2000; 23: 1830-1834.
7. Buse JB, Freeman JL, Edelman SV, Jovanovic L, McGill JB. Serum 1, 5-anhydroglucitol (GlycoMark): a short-term glycemic marker. Diabetes Technol Ther 2003; 5: 355-363.
8. Amanouchi T, Tachibana Y, Akanuma H, et al. Origin and disposal of 1, 5-anhydroglucitol, a major polyol in the human body. Am J Physiol 1992; 263: E268-E273.
9. Akanuma Y, Morita M, Fukuzawa N, Yamanouchi T, Akanuma H. Urinary excretion of 1, 5-anhydro-D-glucitol accompanying glucose excretion in diabetic patients. Diabetologia 1988; 31: 831-835.
10. Stenninger E, Lindqvist A, Aman J, Ostlund I, Schvarcz E. Continuous subcutaneous glucose monitoring system in diabetic mothers during labour and postnatal glucose adaptation of their infants. Diabet Med 2008; 25: 450-454.
11. Rodbard D. Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control. Diabetes Technol Ther 2009; 11(Suppl 1): S55-S67.
12. McDonnell CM, Donath SM, Vidmar SI, Werther GA, Cameron FJ. A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol Ther 2005; 7: 253-263.
13. Molnar GD, Taylor WF, Ho MM. Day-to-day variation of continuously monitored glycaemia: a further measure of diabetic instability. Diabetologia 1972; 8: 342-348.
14. Kovatchev BP, Cox DJ, Gonder-Frederick LA, Young-Hyman D, Schlundt D, Clarke W. Assessment of risk for severe hypoglycemia among adults with IDDM: validation of the low blood glucose index. Diabetes Care 1998; 21: 1870-1875.
15. Yamanouchi T, Akanuma H, Asano T, Konishi C, Akaoka I, Akanuma Y. Reduction and recovery of plasma 1, 5-anhydro-D-glucitol level in diabetes mellitus. Diabetes 1987; 36: 709-715.
16. Nowatzke W, Sarno MJ, Birch NC, Stickle DF, Eden T, Cole TG. Evaluation of an assay for serum 1, 5-anhydroglucitol (GlycoMark) and determination of reference intervals on the Hitachi 917 analyzer. Clin Chim Acta 2004; 350: 201-209.
17. Shi H, Fang J, Yang X, Shen Z, Zhu X. Serum 1, 5-anhydro-D-glucitol as a new clinical marker for glucose metabolism in type 2 diabetics. Chin Med J (Engl) 1999; 112: 571-573.
18. Kovatchev BP, Cox DJ, Kumar A, Gonder-Frederick L, Clarke WL. Algorithmic evaluation of metabolic control and risk of severe hypoglycemia in type 1 and type 2 diabetes using self-monitoring blood glucose data. Diabetes Technol Ther 2003; 5: 817-828.
19. Dworacka M, Winiarska H. The application of plasma 1, 5-anhydro-D-glucitol for monitoring type 2 diabetic patients. Dis Markers 2005; 21: 127-132.
20. Dungan KM, Buse JB, Largay J, et al. 1, 5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care 2006; 29: 1214-1219.
21. Nguyen TM, Rodriguez LM, Mason KJ, Heptulla RA. Serum 1, 5-anhydroglucitol (Glycomark) levels in children with and without type 1 diabetes mellitus. Pediatr Diabetes 2007; 8: 214-219.
22. Kishimoto M, Yamasaki Y, Kubota M, et al. 1, 5-Anhydro-D-glucitol evaluates daily glycemic excursions in well-controlled NIDDM. Diabetes Care 1995; 18: 1156-1159.
23. Robertson DA, Alberti KGMM, Dowseb GK, Zirnmetb P, Tuomilehto J, Gareebood H. Is serum anhydroglucitol an alternative to the oral glucose tolerance test for diabetes screening? Diabet Med 1993; 10: 56-60.